🇺🇸 FDA
Patent

US 9309553

Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus

granted A61KA61K38/45A61K38/465

Quick answer

US patent 9309553 (Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/45, A61K38/465, A61P, A61P11/00